Based in Cambridge, we’re working to rapidly generate exceptionally high-quality, fully human antibodies for treating challenging diseases.Learn more
We are building a rich pipeline of assets in four main therapeutic spaces: immuno-oncology, inflammation, haematology and infectious diseases. Our most advanced assets entered IND-enabling development in 2015 with clinical studies beginning in 2017.View our pipeline
Join us in developing tomorrow's medicines: we're driven by passion for better healthcare and by compassion to make a difference. Join our experienced and successful team and help us to realise our aims.View our vacancies
Dave Chiswell and Paul Kellam explain how Kymouse™ will help tackle disease in key areas.
Partnership with Heptares will develop antibodies that target GPCR proteins acting as checkpoints in cancer development.
Kymab CEO, Dr Dave Chiswell, is interviewed by BBC East Business Correspondent, Richard Bond, explaining how Kymab’s success means it wil...
Kymab strengthens its management team with appointments in immuno-oncology, infectious disease and blood disorders
7 Nov 2016 - 9 Nov 2016 | KoelnMesse - Congress Center North, Cologne, Germany
View event details